---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-25-000032"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:57:41.101157+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Autolus reports Q1 AUCATZYL revenue $9.0M; UK MHRA approval for r/r B-ALL

## Summary
- Q1 2025 AUCATZYL net product revenue $9.0M, first quarter of launch.
- UK MHRA granted conditional marketing authorization for AUCATZYL in r/r B-ALL.
- Net loss $70.2M ($0.26 per share) vs $52.7M ($0.24) in Q1 2024.
- Cash & marketable securities $516.6M; company well-capitalized for launch and trials.
- Phase 1 CARLYSLE data: 3/6 SLE patients complete renal response; Phase 2 LN trial by year-end.

## SEC filing metadata
- accession: 0001730463-25-000032
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046325000032/0001730463-25-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046325000032/autl-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-25-000032
- JSON: https://secwatch.observer/filing/0001730463-25-000032.json
- Plain text: https://secwatch.observer/filing/0001730463-25-000032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.